MSC衍生sEV通过递送miR-22-3p抑制NLRP3炎症小体激活来减轻糖尿病视网膜病变
核心信息
- 论文英文标题: MSC-derived small extracellular vesicles alleviate diabetic retinopathy by delivering miR-22-3p to inhibit NLRP3 inflammasome activation
- 期刊: Stem Cells
- 发表年份: 2023
- DOI: 10.1093/stmcls/sxad078
- PMID/PMCID: 37847598
研究概览
This study aimed to investigate the effect of mesenchymal stem cell (MSC)-derived small extracellular vesicles (sEVs) on diabetic retinopathy (DR) and its underlying mechanism. Our findings indicate that MSC-sEVs might be a potential therapeutic method for DR.
核心发现
In vivo, MSC-sEVs inhibited NLRP3 inflammasome activation, suppressed microglial activation, decreased inflammatory cytokines levels in the retina, and alleviated DR as evidenced by improved histological morphology and blood-retinal barrier function.
Based on miRNA sequencing of MSC-sEVs, bioinformatic software, and dual-luciferase reporter assay, miR-22-3p stood out as the critical molecule for the role of MSC-sEVs in regulating NLRP3 inflammasome activation.
Diabetic rats had lower level of miR-22-3p in their retina than those of control and sEV-treated rats.
Confocal microscopy revealed that sEV could be internalized by microglia both in vivo and in vitro.
研究设计
In vivo, MSC-sEVs were injected intravitreally into diabetic rats to determine the therapeutic efficacy.
In vitro, MSC-sEVs with/without miR-22-3p inhibition were cocultured with advanced glycation end-products (AGEs)-induced microglia with/without NLRP3 overexpression to explore the molecular mechanism.
Echo Biotech 角色
MSC外泌体miRNA测序分析
关联平台: Exoomics®
关联服务与能力: EV miRNA Profiling / Sequencing
关联产品或试剂: 无明确产品引用
参考文献
原始论文: MSC-derived small extracellular vesicles alleviate diabetic retinopathy by delivering miR-22-3p to inhibit NLRP3 inflammasome activation Stem Cells. 2023. DOI: 10.1093/stmcls/sxad078. PMID/PMCID: 37847598.